Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Retail 90-Day Script Option May Be Gaining Traction With Payors

This article was originally published in The Pink Sheet Daily

Executive Summary

CVS is going on the offensive by positioning retail pharmacy 90-day scripts as being competitive with mail order

You may also be interested in...



CVS' Retail Stores, PBM Will Be "Significant Participants" In Medicare – CEO

The pharmacy chain expects higher retail drug utilization under Medicare drug benefit due to employers dropping coverage for retirees who typically used mail-order pharmacies. The absence of mandatory mail provisions in the final Medicare Part D regulations is "good news," CVS says.

CVS' Retail Stores, PBM Will Be "Significant Participants" In Medicare – CEO

The pharmacy chain expects higher retail drug utilization under Medicare drug benefit due to employers dropping coverage for retirees who typically used mail-order pharmacies. The absence of mandatory mail provisions in the final Medicare Part D regulations is "good news," CVS says.

CVS Withdraws From Ohio Pharmacy Network, Cites Lack Of Customer Choice

Failed talks with plan administrator Express Scripts to allow refills of maintenance prescriptions at retail pharmacies led to CVS' withdrawal from the Ohio state employees' Rx plan. The plan requires use of mail order services after a maintenance script is filled two times at a community pharmacy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel